RhAPPcast

In this educational Medication Review, Jennifer Mylod, DNP, provides an overview of the biologic and targeted therapies currently available for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). This video reviews the different mechanisms of action used to target key immune pathways involved in lupus and highlights how these therapies help manage disease activity and improve patient outcomes.

Learn how cur...

In this FAQ video, Amanda Mixon, PA-C, discusses why early intervention is critical in the management of systemic lupus erythematosus (SLE). Early diagnosis and treatment are essential for controlling inflammation, preventing irreversible organ damage, and improving long-term patient outcomes.

This educational discussion reviews the impact of uncontrolled lupus on major organ systems, including the kidneys, heart, lungs, and brain, ...

In this RhAPP Journal Club, Danielle Gatti-Palumbo, a clinical pharmacist in rheumatology, reviews the efficacy and safety of deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in patients with active psoriatic arthritis (PsA). The presentation focuses on 52-week findings from the phase 3 POETYK PsA-1 trial in patients who had not previously received biologic therapy. Danielle explains TYK2 signaling, patient el...

In this FAQ video module, Tiffany Terrell, NP, reviews the role of early intervention and steroid reduction in minimizing long-term organ damage in systemic lupus erythematosus (SLE) and lupus nephritis. This overview highlights the importance of timely treatment, routine kidney monitoring, and controlling inflammation while limiting prolonged corticosteroid exposure.

This episode explores American College of Rheumatology (ACR) reco...

In this RhAPP journal club video module, Danielle Gatti-Palumbo, PharmD reviews the efficacy and safety of nanoencapsulated sirolimus plus pegadricase (NASP) in patients with uncontrolled gout, based on findings from the randomized, placebo-controlled Phase 3 DISSOLVE I and II trials. She explains how nanoencapsulated sirolimus is designed to reduce anti-drug antibody formation and support sustained serum urate lowering with pegadr...

In this RhAPP FAQ video module, Jennifer Mylod, nurse practitioner at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, explains the Total Improvement Score, or TIS, and how it is used to assess treatment response in idiopathic inflammatory myopathies, including myositis and related autoimmune muscle diseases. This episode reviews how the ACR/EULAR Total Improvement Score serves as a composite outcome measure in in...

In this RhAPP FAQ video module, Jennifer Mylod, nurse practitioner at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, discusses how autoantibodies help guide diagnosis, prognosis, disease monitoring, and treatment decisions in idiopathic inflammatory myopathies, including myositis, dermatomyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy. This episode highlights key myositis-specific and...

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, president of RhAPP, is joined by RhAPP board member Kyle George to explore The True Cost of Gout: Work, Wellness, and Daily Life. The discussion examines how uncontrolled gout extends beyond painful flares and swollen joints, affecting mobility, employment, productivity, independence, emotional well-being, relationship...

In this FAQ video module, Jennifer Mylod, nurse practitioner with Arizona Arthritis Rheumatology Associates in Phoenix, Arizona, discusses key diagnostic considerations and limitations of antibody testing in idiopathic inflammatory myopathies, including myositis, dermatomyositis, and other inflammatory muscle diseases. While myositis antibody panels can provide valuable information for diagnosis, prognosis, and disease classificati...

In this RhAPP journal club video module, Danielle Gatti Palumbo, PharmD, reviews the Phase 3 POETYK PsA-2 clinical trial evaluating deucravacitinib in adults with active psoriatic arthritis. Deucravacitinib is an oral, selective tyrosine kinase 2, or TYK2, inhibitor that targets signaling pathways involved in psoriatic arthritis, including interleukin-23 and type I interferons. This randomized, double-blind, placebo-controlled stud...

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon leads a multidisciplinary, case-based discussion titled “Cracking the Code: A Rheum-Derm-Neuro Multispecialty Case Approach to Myositis.” Joined by dermatology clinician Laura Bush and neuromuscular medicine PA Maggie Naclerio, this episode explores the complex and often subtle presentations of myositis, idi...

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon is joined by RhAPP board member Wendy Simmons to explore uncontrolled gout as a systemic inflammatory disease with effects that extend far beyond acute joint pain. The discussion examines how persistent hyperuricemia can lead to monosodium urate crystal deposition, ongoing inflammation, tophi, bone erosion, cartilage da...

In this RhAPP journal club video module, Bharati Bhardwaja, PharmD, BCPS, LSSBB, reviews the Phase 3 TOGETHER-PsA clinical trial and its implications for adults with active psoriatic arthritis who are overweight or have obesity. This study is the first randomized trial to evaluate whether adding the dual GIP/GLP-1 receptor agonist tirzepatide to ixekizumab can improve both rheumatologic and metabolic outcomes.

This episode reviews ...

In this rheumatology FAQ, Audrey Gibson, PA-C, reviews how clinical manifestations and histopathologic features vary across idiopathic inflammatory myopathy subtypes, including dermatomyositis, polymyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, and inclusion body myositis. This clinically focused discussion highlights the key differences in muscle weakness patterns, skin findings, interstitial lung disease...

In this rheumatology FAQ, host Audrey Gibson, PA-C from the Arthritis Center of North Georgia in Gainesville, Georgia, discusses the key unmet needs in the treatment of idiopathic inflammatory myopathies, including myositis, dermatomyositis, immune-mediated necrotizing myopathy, and other rare inflammatory muscle diseases. These complex, heterogeneous autoimmune conditions can be difficult to diagnose and manage, often leading to d...

Stay up to date with the latest advances in rheumatoid arthritis management in this RhAPPcast Fireside Chat episode focused on the SELECT-SWITCH trial and its implications for clinical practice. Hosted by Amanda Mixon, PA-C, this discussion features expert perspectives from Jeannette Hart, PA-C, and James Levine, DO, as they explore treatment decision-making after TNF inhibitor failure and what the latest evidence means for patient...

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Heather Finlayson, PA-C, to discuss treat-to-target strategies in lupus management and how DORIS remission can be applied in real-world clinical practice. This conversation explores what successful lupus care looks like beyond flare management, including steroid minimization, low disease activity, sh...

In this episode of RhAPPcast, the official podcast of the Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by rheumatology pharmacist expert Danielle Gatti Palumbo, PharmD, to explore the expanding role of clinical pharmacists in rheumatology care. This conversation highlights how pharmacists are integrated into multidisciplinary teams to support the management of complex rheumatic diseases through medic...

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Wendy Simmons, PA-C, for Part 2 of the EULAR 2026 Osteoporosis RhAPP Up Series.

Together, they review key osteoporosis abstracts from the 2026 EULAR Congress, including new insights on the use of GLP-1 based therapies in patients taking oral bisphosphonates for osteoporosis and the potential impact on...